These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 31362687

  • 21. An innovative cell-based assay for the detection of modulators of soluble guanylate cyclase.
    Corazza S, Scarabottolo L, Lohmer S, Liberati C.
    Assay Drug Dev Technol; 2006 Apr; 4(2):165-73. PubMed ID: 16712420
    [Abstract] [Full Text] [Related]

  • 22. Soluble guanylate cyclase: a potential therapeutic target for heart failure.
    Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Böhm M, Burnett JC, Campia U, Cleland JG, Collins SP, Fonarow GC, Levy PD, Metra M, Pitt B, Ponikowski P, Sato N, Voors AA, Stasch JP, Butler J, Academic Research Team in Heart Failure (ART-HF).
    Heart Fail Rev; 2013 Mar; 18(2):123-34. PubMed ID: 22622468
    [Abstract] [Full Text] [Related]

  • 23. Molecular variants of soluble guanylyl cyclase affecting cardiovascular risk.
    Wobst J, Rumpf PM, Dang TA, Segura-Puimedon M, Erdmann J, Schunkert H.
    Circ J; 2015 Mar; 79(3):463-9. PubMed ID: 25746521
    [Abstract] [Full Text] [Related]

  • 24. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C, Swan K, Kadowitz P.
    Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
    [Abstract] [Full Text] [Related]

  • 25. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
    Kopra K, Sharina I, Martin E, Härmä H.
    Sci Rep; 2020 Oct 15; 10(1):17469. PubMed ID: 33060787
    [Abstract] [Full Text] [Related]

  • 26. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
    Stasch JP, Hobbs AJ.
    Handb Exp Pharmacol; 2009 Oct 15; (191):277-308. PubMed ID: 19089334
    [Abstract] [Full Text] [Related]

  • 27. Therapeutic Targeting of the Soluble Guanylate Cyclase.
    Makrynitsa GI, Zompra AA, Argyriou AI, Spyroulias GA, Topouzis S.
    Curr Med Chem; 2019 Oct 15; 26(15):2730-2747. PubMed ID: 30621555
    [Abstract] [Full Text] [Related]

  • 28. A Hopeful Prospect of Riociguat as a Soluble Guanylate Cyclase Stimulator for Management of Pressure Ulcers.
    Azadi S, Ashrafi H, Azadi A.
    Curr Drug Discov Technol; 2018 Oct 15; 15(1):20-23. PubMed ID: 28914189
    [Abstract] [Full Text] [Related]

  • 29. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY, Jiang X, Jing ZC.
    Drug Des Devel Ther; 2017 Oct 15; 11():1195-1207. PubMed ID: 28458514
    [Abstract] [Full Text] [Related]

  • 30. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
    Alexandre EC, Leiria LO, Silva FH, Mendes-Silvério CB, Calmasini FB, Davel AP, Mónica FZ, De Nucci G, Antunes E.
    J Pharmacol Exp Ther; 2014 Apr 15; 349(1):2-9. PubMed ID: 24421320
    [Abstract] [Full Text] [Related]

  • 31. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel.
    Dismuke WM, Sharif NA, Ellis DZ.
    Invest Ophthalmol Vis Sci; 2009 Jul 15; 50(7):3353-9. PubMed ID: 19234350
    [Abstract] [Full Text] [Related]

  • 32. A cell-based nitric oxide reporter assay useful for the identification and characterization of modulators of the nitric oxide/guanosine 3',5'-cyclic monophosphate pathway.
    Wunder F, Buehler G, Hüser J, Mundt S, Bechem M, Kalthof B.
    Anal Biochem; 2007 Apr 15; 363(2):219-27. PubMed ID: 17336915
    [Abstract] [Full Text] [Related]

  • 33. C-type natriuretic peptide decreases soluble guanylate cyclase levels by activating the proteasome pathway.
    de Frutos S, Saura M, Rivero-Vilches FJ, Rodriguez-Puyol D, Rodriguez-Puyol M.
    Biochim Biophys Acta; 2003 Dec 07; 1643(1-3):105-12. PubMed ID: 14654233
    [Abstract] [Full Text] [Related]

  • 34. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K, Sydykov A, Tian X, Mamazhakypov A, Neupane B, Luitel H, Weissmann N, Seeger W, Grimminger F, Kretschmer A, Stasch JP, Ghofrani HA, Schermuly RT.
    Int J Cardiol; 2016 Aug 01; 216():85-91. PubMed ID: 27140341
    [Abstract] [Full Text] [Related]

  • 35. Soluble guanylate cyclase modulators in heart failure.
    Mitrovic V, Jovanovic A, Lehinant S.
    Curr Heart Fail Rep; 2011 Mar 01; 8(1):38-44. PubMed ID: 21207207
    [Abstract] [Full Text] [Related]

  • 36. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
    Krishnan SM, Kraehling JR, Eitner F, Bénardeau A, Sandner P.
    Int J Mol Sci; 2018 Jun 09; 19(6):. PubMed ID: 29890734
    [Abstract] [Full Text] [Related]

  • 37. Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential.
    Buys ES, Zimmer DP, Chickering J, Graul R, Chien YT, Profy A, Hadcock JR, Masferrer JL, Milne GT.
    Nitric Oxide; 2018 Aug 01; 78():72-80. PubMed ID: 29859918
    [Abstract] [Full Text] [Related]

  • 38. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview.
    Evora PR, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE.
    Curr Drug Targets; 2012 Aug 01; 13(9):1207-14. PubMed ID: 22716077
    [Abstract] [Full Text] [Related]

  • 39. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C, Kern J, Heitz M, Plas E, Zwerschke W, Mattesich M, Sandner P, Berger P.
    Exp Cell Res; 2015 Nov 01; 338(2):162-9. PubMed ID: 26410556
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.